Showing results (181-190 of 243) with videos related to

Sort By:
Pageof 25
JAMA Oncology|January 13, 2018
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung CancerLaura Mezquita, Edouard Auclin, Roberto Ferrara, et al.
JCO Precision Oncology|October 31, 2022
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine OncologyPatricia Martin-Romano, Laura Mezquita, Antoine Hollebecque, et al.
Lung Cancer (Amsterdam, Netherlands)|May 24, 2022
Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcomeAlice Mogenet, Fabrice Barlesi, Benjamin Besse, et al.
The Journal of Liquid Biopsy|March 3, 2025
Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experienceClaudia Parisi, José Carlos Benitez, Hélène Lecourt, et al.
EJNMMI Research|August 1, 2020
<sup>18</sup>F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI dataFlorent L Besson, Brice Fernandez, Sylvain Faure, et al.
British Journal of Cancer|December 14, 2023
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trialSophie Postel-Vinay, Juan Coves, Matthieu Texier, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2019
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFICJhanelle E Gray, Augusto Villegas, Davey Daniel, et al.
British Journal of Cancer|September 10, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosisAbderaouf Hamza, Pierre Gestraud, Maryam Karimi, et al.
The Lancet. Oncology|August 19, 2019
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysisScott J Antonia, Hossein Borghaei, Suresh S Ramalingam, et al.
Cancer Research|November 13, 2016
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted AgentsAntoine Azan, Peter J Caspers, Tom C Bakker Schut, et al.
Pageof 25